Neophyr (Nitric Oxide)

Nitric Oxide delivered by Neophyr diffuses into the pulmonary endothelium and activates soluble guanylate cyclase. This raises cyclic GMP levels, causing smooth‑muscle relaxation in pulmonary arteries, which lowers pulmonary arterial pressure and enhances oxygen exchange without significant systemic effects.

The dose of Neophyr is individualized and set by the prescribing clinician based on the patient’s condition, severity of pulmonary hypertension, and response to therapy. No fixed dosing regimen is provided in public information; clinicians adjust the inhaled concentration and duration as needed.

Safety data for Neophyr in pregnancy and lactation are limited. It is generally recommended to avoid use unless the potential benefit outweighs the unknown risk to the fetus or infant. Clinicians should discuss possible risks and consider alternative therapies when appropriate.

To request Neophyr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Neophyr delivers nitric oxide, a direct pulmonary vasodilator with rapid onset and short half‑life, offering precise titration. Compared with agents such as inhaled prostacyclin analogues, nitric oxide provides more selective pulmonary effects and easier dose adjustment, though both classes require careful monitoring for hypotension and methemoglobinemia.

Neophyr should be stored at ambient temperature, away from heat sources and direct sunlight. Keep the gas cylinder in its original packaging, ensure the valve is closed when not in use, and follow local regulations for compressed gas handling to maintain product integrity.

Neophyr is administered via a calibrated inhalation system that delivers a controlled concentration of nitric oxide gas to the patient’s airway. Administration is performed by trained healthcare personnel, typically in an intensive‑care or specialized respiratory setting, with continuous monitoring of oxygenation and hemodynamic parameters.

The most serious risks include severe methemoglobinemia, which can impair oxygen delivery, and rebound pulmonary hypertension that may occur after abrupt discontinuation. Both conditions require immediate medical intervention and close monitoring during and after therapy.

Neophyr should be avoided in patients with known hypersensitivity to nitric oxide, those with severe left‑heart failure, uncontrolled systemic hypotension, or significant methemoglobin‑forming disorders. Caution is also advised for individuals receiving other potent vasodilators or agents that increase methemoglobin levels.